Plant · Scientific monograph
Tanacetum parthenium
Feverfew / Santa Maria
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Migraine Prophylaxis, Anti-inflammatory Research, Neurology, Platelet Biology
Research overview
Historical use
Tanacetum parthenium (feverfew) has been used in European folk medicine since at least the first century CE, with records in Dioscorides' De Materia Medica describing it for fevers, headaches, and menstrual irregularities. Medieval herbalists employed it as an emmenagogue and for arthritis, and it was a common cottage-garden remedy in Britain through the 18th and 19th centuries. Pre-1990 literature often catalogued it under the synonym Chrysanthemum parthenium.
Modern research context
Feverfew is primarily investigated as a prophylactic agent for migraine. A 2015 Cochrane systematic review of 6 RCTs (n=561) found low-quality evidence of a reduction in migraine frequency, with Murphy et al. (1988) — the landmark RCT included in the review — reporting approximately 0.6 fewer attacks per month versus placebo [1][3]. A multicentre RCT of the standardized CO2 extract MIG-99 (6.25 mg three times daily) found a significant reduction in attack frequency in a pre-specified subgroup of patients with ≥4 attacks per month at baseline (−1.8 attacks/28 days vs. −0.3 for placebo, P=0.02), though the overall intention-to-treat population did not reach statistical significance [2]. Anti-inflammatory activity attributed to parthenolide-mediated suppression of the NF-κB pathway has been documented in preclinical models, providing a mechanistic basis for the observed clinical signal [4].
Adverse effects
The most commonly reported adverse effects in clinical trials include mouth ulceration (approximately 11% of users), gastrointestinal disturbances (nausea, diarrhea), and mild tachycardia in some participants [4]. An abrupt discontinuation syndrome ('post-feverfew syndrome') involving rebound headache, anxiety, and musculoskeletal symptoms has been described in long-term users [1][4]; gradual dose tapering is advisable.
Contraindications
Feverfew is contraindicated in pregnancy due to documented emmenagogue activity and the theoretical risk of uterine stimulation [4]. It should not be used in patients with known hypersensitivity to members of the Asteraceae (Compositae) family, a class effect documented across sesquiterpene lactone-containing plants of this family [4]. Concurrent use with anticoagulant or antiplatelet agents requires caution given its platelet-inhibitory mechanisms [4].
Clinical and phytochemical data
Used part
Leaves (dried)
Primary active compounds
Parthenolide (sesquiterpene lactone; 0.2–0.5% in leaf glands)
Chrysanthemyl acetate
Camphor
Luteolin (flavonoid)
Apigenin (flavonoid)
Spiroketal enol ethers
Mechanism of action
The primary proposed mechanism of action involves parthenolide, a germacranolide sesquiterpene lactone, acting via two convergent pathways. First, parthenolide alkylates sulfhydryl groups on proteins in and around platelets, inhibiting stimulus-induced release of serotonin — a vasoactive mediator implicated in migraine initiation, as reviewed in the pharmacognosy literature [4]. Second, parthenolide specifically inhibits IKκβ (IκB kinase beta), blocking phosphorylation and degradation of IκB, thereby preventing nuclear translocation of NF-κB and suppressing downstream transcription of pro-inflammatory cytokines including COX-2, TNF-α, and IL-1β [4]. The net effect is inhibition of platelet aggregation and reduction of neurogenic inflammation at the trigeminovascular level. Flavonoid constituents (luteolin, apigenin) may contribute additional antioxidant and phosphodiesterase-inhibitory activity, though their contribution to the clinical migraine effect has not been established in isolation.
Pharmacokinetics
Absorption
No dedicated human pharmacokinetic studies for parthenolide or other Tanacetum parthenium constituents have been identified in the peer-reviewed literature as of this entry. Phytochemical data indicate parthenolide concentrations of 0.2–0.5% in superficial leaf glands, with higher concentrations in fresh versus dried preparations; bioavailability differences between preparations have not been formally quantified in humans [4]. All pharmacokinetic statements below are derived from general sesquiterpene lactone chemistry and phytochemical inference, not from clinical PK studies.
Distribution
No human distribution data are available. Parthenolide is lipophilic (consistent with sesquiterpene lactone class), suggesting potential for tissue partitioning; however, human volume of distribution, plasma protein binding, or tissue concentration data have not been reported in the accessible literature.
Metabolism
No human metabolic data are available. Parthenolide contains an alpha-methylene-gamma-lactone moiety and an epoxide group, which are chemically reactive toward nucleophilic thiol groups; rapid conjugation with glutathione is anticipated based on in vitro chemistry, but CYP450 involvement and human metabolite identification have not been formally characterized.
Excretion
No human excretion data are available. Elimination route and half-life have not been established in clinical pharmacokinetic studies. Given the reactive nature of parthenolide and anticipated rapid hepatic conjugation, urinary excretion of conjugated metabolites is plausible but unconfirmed.
Safety and interactions
Drug interactions
Evidence for specific drug interactions derives primarily from pharmacological inference rather than controlled clinical interaction studies. Parthenolide inhibits platelet aggregation via sulfhydryl alkylation [4]; concurrent use with anticoagulants (e.g., warfarin) or antiplatelet agents (e.g., aspirin, clopidogrel) may additively increase bleeding risk — clinical monitoring is advisable if co-administration occurs. The alpha-methylene-gamma-lactone group of parthenolide has theoretical reactivity with other sulfhydryl-containing drugs, but no formal clinical interaction data are available. Interaction potential with CYP450 substrates has not been established.
Toxicity
No serious adverse events were reported across six RCTs included in the 2015 Cochrane review (n=561) [1]. Adverse effects in clinical trials were described as mild and reversible, including mouth ulcers (~11%), GI disturbance, and mild tachycardia in some participants [4]. Post-feverfew syndrome on abrupt withdrawal has been described but is not classified as a serious adverse event. No formal LD50 data in humans are available; animal and in vitro toxicology data were not systematically reviewed in the identified sources.
Special precautions
Pregnancy
Contraindicated. Feverfew has documented emmenagogue activity in traditional and pharmacological literature, and in vitro data suggest uterine-stimulating properties attributed to parthenolide [4]. No controlled human safety data in pregnancy exist. Avoid throughout pregnancy.
Lactation
Insufficient safety data. Excretion of parthenolide or its metabolites into human breast milk has not been studied. Given the reactive chemical nature of parthenolide and lack of neonatal safety data, use during lactation is not recommended.
Hepatic impairment
No specific clinical data in hepatically impaired patients have been identified. Given the anticipated hepatic metabolism of parthenolide via glutathione conjugation, reduced metabolic clearance is theoretically possible in severe hepatic impairment, but no dose adjustment guidance is available in the literature.
Renal impairment
No specific clinical data in renally impaired patients have been identified. No established contraindication based on available evidence; however, formal pharmacokinetic studies in this population have not been conducted.
Sources and references
- [1] - Wider B, Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev. 2015;(4):CD002286. PMID: 25892430
- [2] - Pfaffenrath V, Diener HC, Fischer M, Friede M, Henneicke-von Zepelin HH. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis — a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia. 2002;22(7):523-32. PMID: 12230594
- [3] - Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet. 1988;2(8604):189-92. PMID: 2899663
- [4] - Pareek A, Suthar M, Rathore GS, Bansal V. Feverfew (Tanacetum parthenium L.): A systematic review. Pharmacognosy Rev. 2011;5(9):103-10. PMID: 22096324